Celltrion Fails To Revoke Rivals' Asthma Drug Patent In UK
A London court on Thursday denied Celltrion's attempt to revoke Genentech and Novartis' patent for omalizumab, instead ruling that Celltrion has infringed its rivals' protections over the asthma drug in the...To view the full article, register now.
Already a subscriber? Click here to view full article